Liver resections in metastatic gastric cancer

HPB

Volumn 12, Issue 9, 2010, Pages 589-596

  Kerkar, Sid P ^a   Kemp, Clinton D ^a   Avital, Itzhak ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gastric cancer; Liver metastases

Indexed keywords

ACLARUBICIN; ANTHRACYCLINE; CISPLATIN; FLUOROURACIL; MITOMYCIN C;

CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER RESECTION; LONG TERM CARE; MORBIDITY; PATHOLOGY; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURGICAL TECHNIQUE;

EID: 78349245940     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00224.x     Document Type: Review

References (41)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. International Agency for Research on Cancer. (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. [Accessed 14 August 2010.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, etal. (2009) Cancer statistics 2009. CA Cancer J Clin 59: 225 - 249.
3. National Cancer Institute. Surveillance epidemiology and end results: stat fact sheets. [Accessed 21 December 2009.
4. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, etal. (2003) Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surg 133: 507 - 511.
5. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, etal. (2001) Hepatic resection for metastatic tumours from gastric cancer. Ann Surg 235: 86 - 91.
6. Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Mühlbacher F, etal. (2002) Analysis of hepatic resection of metastases originating from gastric adenocarcinoma. J Gastrointest Surg 6: 682 - 689.
7. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS,. (2004) Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 240: 808 - 816.
8. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M,. (1995) Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587 - 591.
9. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M, etal. (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37 - 41.
10. Leong T,. (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 21: 673 - 678.
11. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenlam M, Boni C, etal. (2007) Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastro-oesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25: 3205 - 3209.
12. Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, etal. (2004) Longterm survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 34: 654 - 659.
13. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, etal. (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil vs. fluorouracil, doxorubicin, and methotrexate in advanced oesophagogastric cancer. J Clin Oncol 15: 261 - 267.
14. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, etal. (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 236: 397 - 406.
15. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Qne FG,. (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197: 29 - 37.
16. Pawlik TM, Choti MA,. (2007) Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 11: 1057 - 1077.
17. Morise Z, Sugioka A, Hoshimoto S, Kato T, Ikeda M, Uyami I, etal. (2008) The role of hepatectomy for patients with liver metastases of gastric cancer. Hepatogastroenterology 55: 1238 - 1241.
18. Thelen A, Jonas S, Benckert C, Lopez-Hänninen E, Neumann U, Rudolph B, etal. (2008) Liver resection for metastatic gastric cancer. Eur J Surg Oncol 34: 1328 - 1334.
19. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, etal. (2008) Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 19: 1146 - 1153.
20. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, etal. (2009) Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg 394: 647 - 653.
21. Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, etal. (2007) Favourable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 95: 534 - 539.
22. Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, etal. (2007) Liver resection for metastatic gastric cancer: experience with 42 patients including eight longterm survivors. Jpn J Clin Oncol 37: 836 - 842.
23. Roh HR, Suh KS, Lee HJ, Yang HK, Choe KJ, Lee KU,. (2005) Outcome of hepatic resection for metastatic gastric cancer. Am Surg 71: 95 - 99.
24. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, etal. (2003) Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surg 133: 507 - 511.
25. Shirabe K, Shimada M, Matsumata T, Higashi H, Yakeishi Y, Wakiyama S, etal. (2003) Analysis of the prognostic factor for liver metastases of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterology 50: 1560 - 1563.
26. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, etal. (2002) Hepatic resection for metastatic tumours from gastric cancer. Ann Surg 235: 86 - 91.
27. Saiura A, Umekita N, Inoue S, Maeshiro T, Miyamoto S, Matsuiy Y, etal. (2002) Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer. Hepatogastroenterology 49: 1062 - 1065.
28. Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Mühlbacher F, etal. (2002) Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg 6: 682 - 689.
29. Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, etal. (2001) Benefits and limits of hepatic resection for gastric metastases. Am J Surg 181: 279 - 283.
30. Imamura H, Matsuyama Y, Shimada R, Kubota M, Nakayama A, Kobayashi A, etal. (2001) A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. Am J Gastroenterol 96: 3178 - 3184.
31. Fujii K, Fujioka S, Kato K, Machiki Y, Kutsuna Y, Ishikawa A, etal. (2001) Resection of liver metastases from gastric adenocarcinoma. Hepatogastroenterology 48: 368 - 371.
32. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, Plaud B, Ducreux M, Spielmann M, etal. (1998) Resection of liver metastases from a non-colorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 187: 487 - 493.
33. Miyazaki M, Itoh H, Nakagawa K, Ambiru S, Shimizu H, Togawa A, etal. (1997) Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol 92: 490 - 493.
34. Ochiai T, Sasako M, Mizuno S, Kinoshita T, Takayama T, Kosuge T, etal. (1994) Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br J Surg 81: 1175 - 1178.
35. Bines SD, England G, Deziel DJ, Witt TR, Doolas A, Roseman DL, etal. (1993) Synchronous, metachronous, and multiple hepatic resections of liver tumours originating from primary gastric tumours. Surg 114: 799 - 805.
36. Adam R, Chiche L, Aloia T, Elias D, Salmon R, Riuoire M, etal. (2006) Hepatic resection for non-colorectal non-endocrine liver metastases. Ann Surg 244: 524 - 535.
37. Hirai I, Kimura W, Fuse A, Isobe H, Hachiya O, Moriya T, etal. (2006) Surgical management for metastatic liver tumours. Hepatogastroenterology 53: 757 - 763.
38. Page DL, Flemming ID, Fritz A, Balch CM, Haller DG, Morrow M, etal. (2002) American Joint Committee on Cancer Cancer Staging Manual, 6th edn. New York, NY: Birkhauser.
39. Lee J, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, etal. (2007) Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol 18: 88 - 92.
40. Cao W, Yang W, Lou G, Jiang J, Geng M, Xi W, etal. (2009) Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anticancer Drugs 20: 287 - 293.
41. Kerkar SP, Kemp CD, Duffy A, Kammula US, Shrump DS, Kwong KF, etal. (2009) The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy, plus systemic therapy vs. systemic therapy alone. Trials 10: 121.